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Abstract: In Lambert–Eaton myasthenic syndrome (LEMS), antibodies against presynaptic 
voltage-gated calcium channels reduce the quantal release of acetylcholine, causing muscle 
weakness and autonomic dysfunction. More than half of the affected patients have associated 
small cell lung cancer, and thorough screening for an underlying malignancy is crucial. The 
mainstay of treatment for LEMS is symptomatic but immunotherapy is needed in more severely 
affected patients. Symptomatic therapies aim at increasing the concentration of acetylcholine at 
the muscle endplate. While acetylcholinesterase inhibitors were the first drugs to be used for the 
amelioration of symptoms, 3,4-diaminopyridine (3,4-DAP, amifampridine) has been shown to be 
more effective. 3,4-DAP blocks presynaptic potassium channels, thereby prolonging the action 
potential and increasing presynaptic calcium concentrations. This then results in increased quantal 
release of acetylcholine. The efficacy of 3,4-DAP for increasing muscle strength and resting 
compound muscle action potentials has been demonstrated by four placebo-controlled trials. Side 
effects are usually mild, and the most frequently reported are paresthesias. The most common 
serious adverse events are epileptic seizures. 3,4-DAP is currently the treatment of choice in 
patients with Lambert–Eaton myasthenic syndrome.
Keywords: Lambert–Eaton myasthenic syndrome, symptomatic treatment, management, 
3,4-diaminopyridine, amifampridine
An antibody-mediated syndrome
Lambert–Eaton myasthenic syndrome (LEMS) is a disorder of the neuromuscular 
junction, characterized by proximal muscle weakness, depressed tendon reflexes, and 
posttetanic potentiation in addition to autonomic dysfunction.1–3 The clinical response 
of LEMS patients to plasma exchange4 and successful passive transfer experiments 
using patients’ immunoglobulin4–6 led to discovery of serum antibodies to P/Q-type 
voltage-gated calcium channels as the cause of LEMS.7,8 These pathogenic antibod-
ies cause a downregulation of voltage-gated calcium channels, lowering the amount 
of presynaptic calcium and thus reducing the quantal release of acetylcholine.9 For 
10%–15% of voltage-gated calcium channel-antibody negative LEMS patients, other 
antibody targets, namely synaptotagmin and presynaptic M1 muscarinic acetylcholine 
receptors, have been discussed.10 Reduced acetylcholine release at the neuromuscular 
endplate results in decreased frequency of miniature endplate potentials of normal 
amplitude. Following a single nerve impulse, the acetylcholine released is not suf-
ficient to activate most of the postsynaptic muscle fibers, therefore the compound 
muscle action potential (CMAP) is reduced. The CMAP shows a decrement at low 
stimulation frequency. In contrast, at high stimulation frequency, calcium is thought Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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to accumulate in the nerve ending and facilitate acetylcholine 
release, resulting in the characteristic increment. A clinical 
correlate of this phenomenon is seen in improvement of 
previously absent tendon reflexes following a short period 
of forceful muscle contraction.
Autonomic dysfunction is present in the majority of 
LEMS patients and is usually mild.11 The most commonly 
reported symptoms are dry mouth and male impotence. 
Dry eyes, alterations in sudomotor function, constipation 
or impaired bowel control, and bladder dysfunction are also 
found frequently.11,12 Heart rate variability as a measure 
of parasympathetic innervation of the heart is more often 
affected than orthostatic regulation, which is a function of 
the sympathetic nervous system.12 Autoantibodies against 
voltage-gated calcium channels are also thought to underlie 
the autonomic dysfunction, although this view is not unchal-
lenged.11 Sensorimotor neuropathy is not associated with 
autonomic symptoms in LEMS patients.11
LEMS is associated with small cell lung cancer in 
50%–60% of patients,1,13 who show more rapidly progres-
sive LEMS. Older age, a history of smoking, development 
of multiple clinical symptoms within the first 6 months, the 
presence of cerebellar symptoms, presence of Sox1 antibod-
ies, and absence of human leucocyte antigen B8 all increase 
the likelihood of associated small cell lung cancer.14 Recently, 
the Dutch-English LEMS Tumor Association Prediction 
(DELTA-P) score has been developed to distinguish more 
accurately between patients at high risk versus low risk for 
developing small cell lung cancer.15 The presence of LEMS 
appears to improve survival in patients with small cell lung 
cancer, either due to an immune-mediated effect or due to 
earlier diagnosis and treatment of the cancer. Small cell lung 
cancer is usually identified within 2 years of the diagnosis 
of LEMS.14,16
Management
The prognosis of LEMS is profoundly affected by asso-
ciated small cell lung cancer. Therefore, diagnosis of 
LEMS should prompt a vigorous screen for small cell lung 
cancer, including computed tomography of the thorax, 
[18F]-fluordeoxyglucose positron emission tomography, and 
bronchoscopy. In the event of negative test results, these 
investigations should still be repeated every 6 months for 
at least 2 years.15,16 As yet, it is not clear if the DELTA-P 
score helps to identify patients in need of more intensive or 
prolonged screening.
Because LEMS is an antibody-mediated disease, 
immunotherapy is recommended for more severe cases. 
Recommendations for conventional immunosuppression 
are similar to those for myasthenia gravis.17 Prednisolone 
plus a steroid-sparing agent, such as azathioprine, myco-
phenolate mofetil, cyclosporin, or methotrexate, is used. 
Plasmapheresis can stabilize the patient in a LEMS crisis. 
Alternatively, intravenous immunoglobulins have been 
shown in a small randomized, placebo-controlled, cross-over 
trial to improve limb strength in LEMS patients.18 However, 
immunosuppression is only recommended for patients in 
whom symptomatic treatment does not   suffice.19 Thus, this 
review will focus on the nonimmune treatment options 
for LEMS, in particular the use of 3,4-diamionopyridine 
(3,4-DAP, amifampridine), which is now recommended as 
first-line therapy.
A literature search was performed using PubMed and the 
Cochrane Library. In addition, the assessment report of the 
European Medicines Agency for amifampridine (Zenas®, 
now Firdapse®) was consulted.
Improving availability  
of acetylcholine at the muscle 
endplate
Symptoms of LEMS are caused by reduced quantal release 
of acetylcholine. Therefore, symptomatic treatments aim to 
increase acetylcholine concentrations at the neuromuscular 
junction. Cholinesterase inhibitors block degradation of the 
transmitter and were the first symptomatic treament used 
in LEMS cases.20 However, the effects of monotherapy are 
at best minimal,21 and a double-blind, placebo-controlled, 
cross-over study found no effect of pyridostigmine on CMAP 
amplitude and muscle strength.²²
Other symptomatic treatments are aimed at improvement 
of presynaptic acetylcholine release. Guanidine hydrochlo-
ride was first recommended by Lambert to treat LEMS,23 and 
can increase the concentration of free intracellular calcium 
by blocking the respiratory chain and potassium channels, 
thus prolonging the action potential at the nerve terminal, 
or facilitating calcium channels. In vitro studies have dem-
onstrated that guanidine enhances the release of acetylcho-
line, particularly at the beginning of a tetanus, but not later 
during the tetanic train. This explains its effectiveness in 
LEMS with its low initial action potential and its limited 
use in myasthenia gravis. Guanidine has been shown to 
improve electromyographic parameters and muscle strength 
effectively in multiple case reports.21 However, guanidine 
has not been studied in controlled trials because serious side 
effects, especially bone marrow depression and renal failure, 
preclude widespread use of the drug.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Aminopyridines selectively block presynaptic voltage- 
dependent potassium channels, thereby prolonging cell 
membrane depolarization and allowing for more calcium to 
be transported into the nerve ending. The resulting increase 
in intracellular calcium facilitates the vesicular release of 
acetylcholine and enhances impulse transmission at central, 
autonomic, and neuromuscular synapses. 4-Aminopyridine 
(fampridine) was initially used in LEMS, but its use was 
limited by stimulating effects in the central nervous system, 
because it readily crosses the blood–brain barrier. Fampridine 
is twice as toxic and more convulsive than amifampridine in 
laboratory animals after intravenous administration. In vitro 
studies demonstrated that amifampridine is 7–10 times more 
potent than fampridine in enhancing the quantal release of 
acetylcholine.25 Due to its better therapeutic index, amifampri-
dine is now the drug of choice for the symptomatic treatment 
of LEMS.
Pharmacology of  
3,4-diaminopyridine
Chemistry
3,4-DAP is a quaternary ammonium compound that can be 
supplied as the base or as the more stable phosphate salt. It 
is water-soluble and only slightly soluble in organic   solvents. 
Figure 1 shows the chemical structures of 3,4-DAP base 
and salt formulations compared with 4-aminopyridine and 
guanidine.
Primary pharmacodynamics
3,4-DAP blocks fast voltage-gated potassium channels, 
prolonging presynaptic depolarization and thus the action 
potential, resulting in increased release of acetylcholine.26,27 
Additionally, a direct modulation of calcium channels by 
altered potassium channel function is suggested.28
The selective potassium channel-blocking characteristics 
of 3,4-DAP have been studied electrophysiologically in 
murine triangularis sterni preparations.29 At a concentration of 
10 mM, 3,4-DAP has been found to be able to reverse a 70% 
reduction in twitch height induced by 1–5 mM   tubocurarine, 
a competitive acetylcholine antagonist. In a study of muscle 
preparations from young and old adult male Fisher rats, 
3,4-DAP increased the isometric twitch force by 180% in 
tissue from young animals, whereas the increase was sig-
nificantly lower (140%) in older animals.30
Secondary pharmacodynamics
3,4-DAP can affect the cardiovascular, nervous, and gas-
trointestinal systems as part of its secondary pharmaco-
dynamic profile. In vitro, 3,4-DAP can modulate cardiac 
conduction and induce phasic contractions in different 
arteries from several species. Additionally, 3,4-DAP can 
stimulate potassium-evoked dopamine and noradrenaline 
release in rat hippocampal slices and upregulate acetylcho-
line release in the brain. Finally, 3,4-DAP can potentiate 
adrenergic and cholinergic neuromuscular transmission in 
the gatrointestinal tract.
3,4-DAP has been demonstrated to increase blood pres-
sure in a dose-dependent manner, induce salivation in the 
cat, and induce full dose-dependent miosis in anesthesized 
rats.31 There are no studies on secondary pharmacodynamics 
in humans.
Pharmacokinetics
There are limited data on the pharmacokinetics of 3,4-DAP. 
In a study of patients with multiple sclerosis, 3,4-DAP base 
was rapidly absorbed after oral administration and had a 
serum half-life from 20 minutes to 2 hours, with considerable 
inter-individual variability.32 After intravenous injection of 
10 mg into LEMS patients, peak plasma concentration (Cmax) 
was 68 ± 19 ng/mL, and the average plasma concentration 
half-life was 58 ± 25 (range 29–110) minutes. Compartmental 
analysis demonstrated a mean clearance of 1.97 L/min. The 
pharmacokinetics of 3,4-DAP were not significantly affected 
by cotreatment with pyridostigmine.²² In LEMS patients, 
clinical improvement is seen within 5 minutes of intravenous 
administration of 3,4-DAP 8 –9 mg. The maximal effect after 
oral administration is seen after 1.5 hours, with treatment 
effects maintained for 3–8 hours. Effective oral doses are 
approximately three times those of the same doses given 
intravenously.33 A bioequivalence study (DAPSEL) com-
paring the 3,4-DAP base and phosphate salt formulations 
showed a higher Cmax and a shorter time to peak concentra-
tion for the salt.31
There are no human data for 3,4-DAP on protein binding, 
metabolism, excretion, or drug interactions apart from the 
data described above.22 There are also no data on special pop-
ulations, such as those with hepatic or renal impairment.
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Figure 1 Chemical structures of potassium channel blockers used experimentally 
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Toxicity
The LD50 is 13 mg/kg in mice after intravenous injection, 
20 mg/kg after peritoneal injection, and 35 mg/kg after sub-
cutaneous injection. Death in mice is due to uncontrolled 
convulsions.33
Clinical use of 3,4-DAP
The first report on the use of 3,4-DAP in LEMS patients 
showed marked improvement of muscle function in three 
women treated with 3,4-DAP 6–9 mg intravenously four 
times daily or 18 mg orally four times daily.34 Up until now, 
there have been four double-blind, placebo-controlled tri-
als investigating the effectiveness of 3,4-DAP in LEMS, 
involving a total of 54 patients (Table 1). Three trials had 
a crossover design, and one had a parallel-group design. 
In all trial participants, the diagnosis of LEMS was based on a 
typical clinical picture, including proximal muscle weakness 
with or without absent tendon reflexes or dysautonomia, and 
confirmed by pathognomonic electrophysiological findings 
of decreased resting CMAP amplitude in a hand muscle, and 
facilitation of more than 100% after 10 seconds of maximal 
voluntary contraction. The primary outcome measure was 
a change in quantitative myasthenia gravis (QMG) score or 
limb muscle strength assessed by myometry. The second-
ary outcome measure was improvement in resting CMAP 
amplitude.
McEvoy et al35 studied 12 LEMS patients in a double-
blind, placebo-controlled, crossover pivotal trial. The first 
8 days were conducted as an open-label phase, during which 
3,4-DAP was given in increasing doses up to 25 mg orally 
four times per day. In the double-blind, cross-over phase, 
patients were randomly assigned to either placebo or the 
maximally tolerated dose of 3,4-DAP for 3 days, and then 
received the alternate regimen for another 3 days. Outcome 
was measured using the neurological disability score, 
including strength of 25 muscles and the activity of five 
tendon reflexes, isometric strength of bilateral elbow and 
wrist flexion, knee extension, and ankle dorsiflexion, and 
electrophysiological parameters, ie, resting CMAP ampli-
tudes, decrement during 2 Hz repetitive stimulation, and 
increment after 10 seconds of voluntary contraction on days 
1, 3, 5, 9, 12, and 15. Additionally, autonomic function was 
assessed quantitatively at baseline and during the maximal 
dose of the open-label phase, including sweat production, 
salivation, orthostasis, and heart rate   variability. The 
neurological disability score was lowered by treatment 
in the open-label phase and was significantly decreased 
compared with placebo in the double-blind phase.   Isometric 
strength also improved significantly with   treatment. Arm 
strength increased from 70% to 81% of normal, leg strength 
from 45% to 65%. The average resting CMAP amplitudes 
increased from 2.9 mV to 5.0 mV in the arm and from 
1.6 mV to 3.1 mV in the leg (compared with 2.8 mV and 
1.8 mV , respectively, after placebo). Decrements and incre-
ments showed no treatment-related changes, nor were any 
of the autonomic function tests altered, although all the 
patients complained of dry mouth (n = 6) but reported an 
improvement after treatment, suggesting that the tests for 
salivation were insensitive. Nine patients were followed 
up for 15 months on 3,4-DAP treament, four of whom 
had additional pyridostigmine. No significant decline in 
the effectiveness of 3,4-DAP was noted during this time. 
Ten of twelve patients noticed paresthesias while taking 
3,4-DAP. Limitations of this study were the limited outcome 
measures and the lack of definition of primary or secondary 
outcome measures.
Table 1 Randomized, placebo-controlled trials with 3,4-diaminopyridine in patients with Lambert–eaton myasthenic syndrome
Reference Trial design Outcome
Mcevoy et al35 n = 12, double-blind, placebo-controlled, cross-over, maximum  
tolerated dose of 3,4-DAP (up to 100 mg/day) for 3 days
improved NDS score, isometric muscle strength and  
resting CMAP amplitudes, decrement and increment  
unchanged, quantitative autonomic tests unchanged
Sanders et al36 n = 26 (12 with 3,4-DAP, 14 with placebo), parallel-group,  
3,4-DAP 60 mg/day or placebo for 6 days
improved QMG score and resting CMAP amplitudes
wirtz et al22 n = 9, double-blind, placebo-controlled, double-dummy,  
cross-over, 3,4-DAP 10 mg iv, pyridostigmine 2 mg iv, both  
drugs together or placebo, functional assessments every  
20 minutes after administration up to 170 minutes
improved isometric muscle strength and resting CMAP   
amplitudes
Oh et al37 n = 8, double-blind, placebo-controlled, cross-over, 3,4-DAP  
15–80 mg/day orally or placebo for 8 days (n = 3) or  
30–75 mg/day orally for 3 days (n = 4), one dropout
improvement of subjective symptoms Score, LeMS  
classification, MRC score of 22 muscles and QMC as  
well as resting CMAP amplitude, unchanged decrement   
and increment
Abbreviations: 3,4-DAP, 3,4-diaminopyridine; CMAP, compound muscle action potential; iv, intravenous; LeMS, Lambert–eaton myasthenic syndrome; MRC, Medical 
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Sanders et al36 studied 26 LEMS patients in a two-arm, 
parallel-treatment protocol. Twelve patients were randomly 
assigned to 3,4-DAP 20 mg three times per day for 6 days. 
The primary outcome measure was muscle strength assessed 
using the QMG score (range 0–39) on the fifth and sixth days 
of study drug administration. Changes in resting CMAP 
amplitudes were used as the secondary outcome measure. 
After six days, QMG scores were improved by an average 
of two points in the group receiving 3,4-DAP, but worsened 
by 0.25 points in the placebo group (P = 0.01). Median 
resting CMAP amplitudes showed an increase of 1.3 mV 
(+64%) in the patients receiving 3,4-DAP, but decreased by 
0.1 mV (3%) in the placebo group (P , 0.001). After the 
blinded phase, 25 patients continued taking 3,4-DAP, usually 
together with pyridostigmine. All but three patients improved 
by at least two QMG points while taking 3,4-DAP. In more 
than half of the patients, the optimum clinical response was 
achieved with 30 mg or 40 mg of 3,4-DAP per day. The 
authors mention that during the open-label phase, 13 patients 
who improved while taking open-label 3,4-DAP had a fur-
ther symptomatic improvement when pyridostigmine was 
added, but this report was not backed up with quantitative 
data. Reported side effects were minimal. Four of 14 patients 
taking 3,4-DAP in the blinded phase and eight of 22 patients 
in the open-label phase complained of perioral and/or digi-
tal paresthesias. No changes in blood tests for renal, liver, 
hematologic, or endocrine function were observed acutely 
or after 6 months in the open-label phase.
Wirtz et al22 performed a randomized, placebo-controlled, 
double-dummy, cross-over study in nine voltage-gated 
calcium channel-positive LEMS patients. They compared 
the effects of 3,4-DAP, pyridostigmine, the combination of 
both drugs, and placebo, on muscle strength and results of 
repetitive nerve stimulation. They also included pharmacoki-
netic and pharmacodynamic data. Patients were treated with 
3,4-DAP 10 mg intravenously, pyridostigmine 2 mg intrave-
nously, both drugs, or placebo. Drug effects were measured 
every 20 minutes up to 170 minutes after administration. 
  Isometric muscle strength of hip flexion and CMAP ampli-
tudes of the hypothenar muscle were used as primary outcome 
measures, with a CMAP decrement after 3 Hz stimulation and 
an increment after maximum voluntary contraction used as 
secondary outcome measures. Muscle strength and CMAP 
amplitude increased significantly compared with placebo 
(mean-time averaged difference 23 Newtons and 0.9 mV, 
respectively) and with both drugs combined (26 Newtons 
and 1.1 mV, respectively), but not with pyridostigmine 
alone. The combination therapy provided a slight reduction 
in decrement compared with 3,4-DAP alone, but no other 
beneficial effects favoring the combination therapy were 
observed. Concentration-effect analysis revealed that the 
neuromuscular effects lasted longer than would be suggested 
by the 1-hour plasma half-life of 3,4-DAP, supporting a three 
to four times daily dosing regimen. Two patients withdrew 
from the study after three treatments due to pain in the arm 
at the injection site.
Oh et al37 conducted a randomized, crossover study in 
eight patients with LEMS. Pyridostigmine was discontin-
ued for at least 24 hours before and during the trial. One 
patient withdrew from the study due to a treatment-related 
side effect after the first phase (chills, shortness of breath, 
weakness, upset stomach, and difficulty sleeping). Patient 
recruitment took place over 12 years and the study design 
was altered after the first three cases. The first group was 
treated for 8 days each in the 3,4-DAP and the placebo phase. 
For the second group, both phases were reduced to 3 days. 
The first group initially received 3,4-DAP 15 mg which 
was gradually increased to 80 mg in the active phase, the 
second group initially received 3,4-DAP 30 mg/day which 
was gradually increased to 75 mg/day in the active phase. 
Clinical outcome was assessed using a subjective symptoms 
score (range 0–3), the LEMS classification (a modified Medi-
cal Research Council [MRC] grade of iliopsoas muscles, 
range 0–3), the MRC score of 22 muscles (range 0–110), and 
the QMG score. Electrophysiologically, CMAP amplitudes 
of abductor digiti quinti muscle, decremental response at 
3 Hz, increments after 30 seconds of exercise, and the results 
of single-fiber electromyography in the extensor digitorum 
communis muscle were examined. Patients treated with 
3,4-DAP improved in all four clinical outcome measures 
compared with the placebo group. The highest statistical 
significance was demonstrated in the LEMS classifica-
tion. While the median baseline value was 1, it was 0 after 
3,4-DAP treatment and 1.5 with placebo. Of the electrophysi-
ological measures, only resting CMAP amplitudes showed 
a significant improvement (mean baseline 3.1 mV; 3,4-DAP 
5.0 mV; placebo 2.4 mV). Four patients were followed up 
long-term in an open-label phase. Three patients received 
3,4-DAP 30 mg/day, with or without pyridostigmine, and 
two of them reported sustained benefit over 1 and 4 years, 
respectively. The third patient took 3,4-DAP up to 70 mg/day, 
but then switched to guanidine hydrochloride due to a better 
clinical effect. The fourth patient discontinued 3,4-DAP and 
carried on with pyridostigmine monotherapy due to the lack 
of additional benefit from 3,4-DAP.37 Shortcomings of this 
study were the change in design during this study, with low Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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numbers of participants and a lack of definition of primary 
and secondary outcome measures.
The 2011 update of the Cochrane review on treatment 
for LEMS summarizes the available data.38 A meta-analysis 
showed that the QMG score obtained after 3–8 days of trea-
ment was likely to improve by a mean of 2.44 points (95% 
confidence interval [CI]: 1.22–3.6). The meta-analysis also 
revealed a mean improvement of the secondary endpoint, 
resting CMAP amplitudes, of 1.36 mV (95% confidence 
interval 0.99 to 1.72). The risk of bias was determined to be 
low and the quality of evidence moderate to high.
In addition, there are case reports on the effectiveness of 
3,4-DAP to treat autonomic dysfunction.39,40 However, there 
may be a publication bias since negative outcomes are less 
likely to be published.
Safety and tolerability  
of 3,4-diaminopyridine
In total, about 2300 people have been exposed to 3,4-DAP, 
among these are around 300 LEMS patients.31 The most 
frequent serious adverse events are seizures. McEvoy et al35 
reported a seizure in a patient shortly after the daily dose 
had been increased from 90 mg to 100 mg and the daily 
dose of pyridostigmine was doubled from 120 mg to 240 mg. 
Seizures did not recur with a daily dose of 3,4-DAP 40 mg. 
In another study of 45 patients with LEMS treated with 
3,4-DAP, three patients suffered seizures. One patient with 
metastatic cancer in the brain had a seizure when taking 
3,4-DAP 60 mg/day. The second patient developed seizures 
under cotreatment of 3,4-DAP 100 mg/day and toxic doses 
of theophylline, but seizures did not recur after theophylline 
was discontinued. One patient with a seizure on 100 mg/day 
continued to take 3,4-DAP at a lower dose and continued to 
be seizure-free over 10 years. The risk of seizures appears 
to be dose-dependent. Therefore, the authors recommend a 
maximal dose of 80 mg/day.36
Other reported serious adverse events are one case each 
of chorea and myoclonia. In the DAPSEL bioequivalence 
study, elevation of liver enzymes was seen in a previously 
healthy subject which returned to normal 1 month after dis-
continuation of 3,4-DAP.31
Serious cardiovascular events were reported in two 
cases. One followed iatrogenic intoxication and occurred 
in a 65-year-old woman receiving 60 mg instead of 10 mg 
six times per day. She presented with general   weakness, 
whole body paresthesias, nausea and vomiting, and 
  supraventricular tachycardia. She subsequently developed 
severe seizures with acute respiratory failure and cardiac 
arrest. After withdrawal of 3,4-DAP she recovered well.41 The 
second case was a myocardial infarction a few weeks after 
3,4-DAP had been commenced. The authors considered the 
event to be a possible “result of sudden increase of physical 
activity”.42 This study also reported bronchial hypersecretion 
and provocation of bronchial asthma.
Effects on QTc levels were examined in the DAPSEL 
study. No increase in QTc was observed, but only relatively 
low doses (3,4-DAP 10 mg or 20 mg) were administered. 
One case report described a 57-year-old man with LEMS 
and euthyroid Hashimoto’s disease, who was treated with 
3,4-DAP 90 mg/d and azathioprine 100 mg/d, and showed a 
slight prolongation of the QTc interval (0.46 msec, normal 
range 0.36–0.44 msec).31
Adverse events were reported in 51 LEMS patients from 
four placebo-controlled trials. Most commonly observed 
were perioral or digital paresthesias with daily doses as low 
as 10 mg, starting about 1 hour after oral administration of 
3,4-DAP. Some patients complained of transient dizziness or 
fatigue. Symptoms resolved with dose reduction. Abdominal 
pain, epigastric distress, or abdominal cramps were also 
frequently reported to occur under treatment with 3,4-DAP. 
The adverse events reported in the placebo-controlled studies 
of LEMS patients are summarized in Table 2.43
The largest safety study of 3,4-DAP in clinical practice 
was carried out as an observational, retrospective cohort 
study involving 669 patients, mostly suffering from multiple 
sclerosis, but including three patients with LEMS.44 The 
patients with multiple sclerosis received 3,4-DAP 20–30 mg/
day, and the LEMS patients received higher doses of 
30, 50 and 80 mg/day. Six serious adverse events were 
reported, ie, three patients with de novo or aggravated seizures, 
one with left-sided paresthesias requiring hospitalization, and 
Table  2  Adverse  events  related  to  3,4-DAP  treatment  in 
Lambert–eaton myasthenic syndrome
Adverse event Patients (n = 51) %
SAE
Seizure 1 2
AE
Paresthesias 22 43
Fatigue 6 12
epigastric distress 6 12
Sleeplessness 5 10
Shortness of breath 1 2
increased tearing 1 2
Urinary urge 1 2
Pain in arm of iv administration 8/9 89
Note: Data from references22,35–37 as summarized in wirtz et al.43
Abbreviations: 3,4-DAP, 3,4-diaminopyridine; Ae, adverse events; SAe, serious 
adverse events; iv, intravenous.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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two with cardiovascular disorders. Drug-induced hepatitis 
was diagnosed in one patient with multiple sclerosis who 
had received 3,4-DAP 30 mg/day and also had had four 
courses of mitoxantron. In total, 18.2% of the patients showed 
adverse events, most of which were mild to moderate and did 
not lead to discontinuation of the drug. Most common were 
paresthesias, followed by sleep disturbances, abdominal pain, 
and nausea and vomiting.44
In the DAPSEL study, 40 adverse events were reported in 
26 healthy volunteers, 25 of which were paresthesias, mainly 
perioral as described in the 3,4-DAP-treated patients. All but 
one adverse event (elevation of liver enzymes as described 
above) were considered minor and did not lead to premature 
withdrawal.
In total, 114 patients were treated under the Therapeutic 
Use Protocol in France, and among these were 39 LEMS 
patients, with 25 adverse events in 13 case reports from 
eleven patients. Of the 13 reports, two were serious. The 
gastrointestinal system was most commonly affected by 
treatment-related adverse events (14.7%), and the most com-
mon individual adverse events were paresthesias (4.9%) and 
nausea and vomiting (3.6%).31
Laboratory tests for renal, hematological, and endocrine 
functions have not revealed any adverse effects of 3,4-DAP. 
However, elevated liver enzymes were reported in one patient 
on a daily dose of 60 mg/day, a healthy volunteer on a dose 
of 30 mg/day, and a patient on 30 mg/day with pretreatment 
elevation of gamma glutamyl transpeptidase.31 There are no 
data on safety in special populations, such as those with renal 
or hepatic impairment.
Because patients with LEMS are extremely sensitive to 
depolarizing and nondepolarizing muscle relaxants (succinyl-
choline, turbocurarine), reduced doses of these drugs should 
be used for neuromuscular blockade during anesthesia, and 
should be avoided where possible. If their use is required, 
neuromuscular transmission should be monitored closely. 
3,4-DAP should be continued up to the time of surgery and 
recommenced as soon as possible.31
Discussion
Four placebo-controlled trials have demonstrated that 
3,4-DAP effectively improves muscle strength and resting 
CMAP in patients with LEMS. Because autonomic symp-
toms are also caused by impaired acetylcholine release, 
3,4-DAP should also treat dysautonomia in LEMS patients. 
  However, despite anecdotal reports of effectiveness, McEvoy 
et al35 found no effect on several quantitative measures of 
autonomic function. This aspect should be studied further, 
bearing in mind the impact of autonomic dysfunction on 
quality of life in patients with LEMS. An additional effect 
of pyridostigmine used as a cotreatment with 3,4-DAP was 
claimed in several reports, but this was not supported by a 
recent small comparative trial. Larger trials may be needed 
to assess moderate treatment effects.
All the 3,4-DAP treatment trials used the base, either as 
a formulation for oral or for intravenous use. The availability 
of 3,4-DAP varies widely across Europe and the US, being 
distributed only through selected pharmacies, commonly 
associated with specialized centers. The more stable phos-
phate salt formulation of 3,4-DAP was granted orphan drug 
status in 2002 by the European Medicines Agency. In the US, 
3,4-DAP also received orphan drug status by the Food and 
Drug Administration, but was not approved for general use, so 
was available only through ad hoc preparations in compound-
ing pharmacies. In December 2009, 3,4-DAP phosphate 
received marketing authorization in the European Union for 
the symptomatic treament of LEMS in adults. However, the 
European Medicines Agency expressed concerns about the 
comparability of the pharmacokinetics of the 3,4-DAP base 
and phosphate salt formulations.
Because the most serious adverse events appear to be 
dose-dependent, the maximal daily dose was reduced from 
80 mg/day to 60 mg/day. Further studies on safety issues 
with higher doses and on long-term efficacy are needed. The 
marketing authorization required a patient registry to be set 
up, including measures of efficacy and addressing several of 
the safety issues, including occurrence of seizures, movement 
disorders, cardiac effects, carcinogenicity, safety in special 
populations such as those with hepatic or renal impairment, 
and pharmacokinetic data. Additionally, a thorough QT/cor-
rected QT study was requested by the European Medicines 
Agency. Because the metabolism of 3,4-DAP has neither 
been studied in vitro nor in vivo, the European Medicines 
Agency have requested in vitro studies assessing the enzymes 
involved in metabolism of 3,4-DAP and the influence of the 
drug on the activity of several liver enzymes. The potential 
for enzyme induction will be tested and metabolites of 
3,4-DAP analyzed. Whether this additional postmarketing 
workup justifies the considerable price difference between 
the 3,4-DAP base formulation and the phosphate salt is 
currently a matter of debate between the manufacturer and 
several health authorities.
Conclusion
3,4-DAP is recommended as first-line symptomatic 
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Federation of Neurological Diseases. It should be offered 
to all patients suffering from this rare disease, which affects 
approximately one in 100,000 individuals in Europe and 
the US. Dosing is recommended to start at 5 mg three times 
a day and can be increased up to 60 mg/day in 3–4 daily 
doses. It is contraindicated in patients with epilepsy. A warn-
ing is issued regarding risk groups, dose-dependency, and 
comedication with drugs that lower the seizure threshold. 
With respect to cardiac function, 3,4-DAP is contraindi-
cated in patients on sultopride, those with congenital QT 
syndromes, and those taking other drugs known to prolong 
the QTc interval or to promote torsades de pointes. A warn-
ing is issued regarding cotreatment with QTc-prolonging 
drugs. Clinical and electrocardiographic monitoring is 
recommended at initiation of the drug and yearly thereafter. 
3,4-DAP is also contraindicated in patients with uncon-
trolled asthma, who should be closely monitored. While 
3,4-DAP will remain the drug of choice for LEMS patients 
in the coming years, ultimately there is a need to develop 
specific immunotherapies targeting their aberrant produc-
tion of pathogenic antibodies.
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